Login to Your Account



Firdapse cardiac safety study hits endpoint; LEMS data next

By Marie Powers
Staff Writer

Wednesday, January 8, 2014
The first formal human cardiac safety study of Firdapse (amifampridine phosphate) met its pre-specified endpoint, demonstrating no effect on heart rate or cardiac depolarization when administered at and above therapeutic levels. The findings boosted prospects for Catalyst Pharmaceutical Partners Inc., who jointly funded the study with Biomarin Pharmaceutical Inc., which conducted the study.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription